Can bladder carcinoma in situ (CIS) be found in single or multiple lesions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Bladder Carcinoma In Situ: Single vs Multiple Lesions

Bladder carcinoma in situ (CIS) can present as either single or multiple lesions, though multifocal disease is more common and carries a worse prognosis. 1

Presentation Patterns of CIS

CIS typically manifests in three distinct clinical scenarios:

  • Primary CIS occurs as an isolated finding without associated papillary tumors, representing less than 3% of all urothelial neoplasms 2
  • Concurrent CIS appears simultaneously with papillary tumors and is always associated with multiple papillary lesions 3
  • Secondary CIS develops during follow-up after treatment of previous bladder cancer 2, 4

Multifocality is the Rule, Not the Exception

The evidence strongly indicates that CIS is predominantly a multifocal disease:

  • When CIS occurs concurrently with papillary tumors, it is always associated with multiple papillary lesions, never solitary ones 3
  • Multifocal CIS lesions are identified as a particularly high-risk feature requiring more aggressive management 1
  • The simultaneous presence of CIS can extend beyond the bladder, with prostatic urethral involvement found in 46% of patients and ureteral involvement in 74% 3

Clinical Implications of Lesion Multiplicity

Multifocal disease significantly impacts prognosis and treatment decisions:

  • Multifocal CIS lesions are specifically categorized as high-risk disease that may warrant early cystectomy rather than repeat TURBT 1
  • The presence of multifocal disease is one of the most important prognostic factors, along with prostatic urethral involvement and response to BCG therapy 2
  • Progression to invasive cancer or death from disease is unusual in primary CIS but common when CIS is associated with other bladder cancers 4

Detection Challenges with Flat Lesions

CIS presents unique diagnostic challenges regardless of whether it is single or multiple:

  • CIS is often missed by standard white light cystoscopy because it appears as flat lesions that can range from normal-appearing mucosa to areas indistinguishable from inflammation 1, 5
  • Blue light cystoscopy detects CIS at significantly higher rates than white light cystoscopy (40.8% more CIS lesions detected; P<.001) 1
  • Small or multifocal lesions are particularly difficult to detect with standard white light cystoscopy 1

Diagnostic Approach for Suspected CIS

When CIS is suspected or known, the following biopsy strategy is recommended:

  • Multiple selective and/or random biopsies should be performed 1
  • Additional biopsies adjacent to any papillary tumor are necessary 1
  • Prostatic urethral biopsy should be considered given the high rate of prostatic involvement 1

Treatment Implications

The treatment approach does not fundamentally differ based on single versus multiple lesions, but multifocality affects prognosis:

  • Standard therapy for CIS is resection followed by intravesical BCG therapy (category 1 recommendation), given once weekly for 6 weeks 1, 6
  • For patients with multifocal high-risk disease, early cystectomy may be preferred over bladder preservation 1
  • BCG instillation remains effective in 87% of CIS patients regardless of lesion number 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[The progress pattern of carcinoma in situ of the urinary bladder].

Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1991

Research

Carcinoma in situ of the bladder: why is it underdetected?

Current opinion in urology, 2020

Guideline

Management of High-Grade T1 Bladder Tumors

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.